Industry

DUBLIN–(BUSINESS WIRE)–The “Pharmacies and Healthcare Stores Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. The global pharmacies and healthcare stores market is expected to grow from $1,093.87 billion in 2021 to $1,202.94 billion in 2022 at a compound annual growth rate (CAGR) of 10%. The market is expected to grow to $1,673.56 … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Surgical Sealants And Adhesives Global Market Report 2022” report has been added to ResearchAndMarkets.com’s offering. Major players in the surgical sealants and adhesives market are Baxter International Inc., B. Braun Melsungen AG, Cohera Medical, Inc., CryoLife Inc., C.R. Bard Inc., CSL Limited (CSL Behring), Johnson & Johnson (Ethicon, Inc.), Sanofi, Ocular Therapeutix Inc., … [Read more…]

New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory patients A comparative model suggests an improvement in SVR35 and TSS50 in JAK inhibitor-naïve myelofibrosis patients treated with pelabresib plus ruxolitinib over JAK inhibitors as monotherapy Additional presentations include positive interim data from the MANIFEST Phase 2 trial and … [Read more…]

– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate – – 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of Complete Responses in first four cycles – – 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event – – Primarily, Grade 3 AESIs to Date Occurred … [Read more…]

Overall response rate of 70.1% and complete response rate of 33.3% in heavily pretreated patients; median duration of response of 13.7 months Safety profile substantially consistent with prior findings Preparing for potential submission of a Biologics License Application to the FDA Cami data and diffuse large B-cell lymphoma posters to be presented today at the … [Read more…]

– Long-term data at the European Hematology Association (EHA) 2022 Congress expands understanding of the impact of Genentech medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatment – – Updated data from Phase III CLL14 study of Venclexta (venetoclax) plus Gazyva (obinutuzumab) showed more … [Read more…]

PRAGUE–(BUSINESS WIRE)–Ahead of the start of the Czech Presidency of the Council of the EU in July, the think tank Centre for Economic and Market Analysis (CETA) published the comparative study “A new approach towards tobacco legislation: the case for harm reduction in CEE and the EU” at an event in Prague. It presents a … [Read more…]

LOS ANGELES–(BUSINESS WIRE)–Consensus Cloud Solutions, Inc. (NASDAQ: CCSI) (the “Company” or “Consensus”) announced today the pricing of the previously announced underwritten offering of 2,000,000 shares of its common stock currently owned by Ziff Davis, Inc. (“Ziff Davis”), Consensus’s former parent company at a price of $41.00 per share (before underwriting discounts and commissions). Consensus is … [Read more…]

If approved, eli-cel will be the first and only gene therapy for the treatment of early active CALD, a rare neurodegenerative disease that primarily affects young children and leads to irreversible loss of neurologic function and death PDUFA goal date is set for September 16, 2022 SOMERVILLE, Mass.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq: BLUE) today announced … [Read more…]

Early-career scientists receive funding to pursue arthritis and related autoimmune disease research IRVINE, Calif.–(BUSINESS WIRE)–The Arthritis National Research Foundation (ANRF) today announced the 19 early-career scientists who will receive grant funding and make up the 2022-23 cohort. The eight first-year grantees will each receive $100,000 and for the first time, second year grantees will be … [Read more…]